Octreoscan

Octreoscan is a brand name of indium pentetreotide in-111, approved by the FDA in the following formulation(s):

OCTREOSCAN (indium in-111 pentetreotide kit - injectable; injection)

• 
  Manufacturer: MALLINCKRODT
  
  Approval date: June 2, 1994
  
  Strength(s): 3mCi/ML ^[RLD]

Has a generic version of Octreoscan been approved?

No. There is currently no therapeutically equivalent version of Octreoscan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Octreoscan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
  Patent 5,384,113
  Issued: January 24, 1995
  Inventor(s): Deutsch; Edward A. & Goedemans; Wilhelmus T. & Maria de Jong; Martinus T. & Miller; Kathleen M. & Brodack; James W.
  Assignee(s): Mallinckrodt Medical, Inc.
  Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol and ascorbic acid to inhibit autoradiolysis of radiolabeled peptides.
  
  Patent expiration dates:
  
  
  • January 24, 2012
    
    ✓ 
    Drug product
  
  



• 
  Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
  Patent 5,753,627
  Issued: May 19, 1998
  Inventor(s): Albert; Rainer & Krenning; Eric P. & Lamberts; Steven W. J. & Pless; Janos
  Assignee(s): Novartis AG
  Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
    ✓ 
    Patent use: METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
  
  



• 
  Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
  Patent 5,776,894
  Issued: July 7, 1998
  Inventor(s): Albert; Rainer & Krenning; Eric P. & Lamberts; Steven W. J. & Pless; Janos
  Assignee(s): Novartis AG
  Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.
  
  Patent expiration dates:
  
  
  • July 7, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...